A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2

(2011) N. C. Munshi et al.   BLOOD

Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders

(2011) Jooeun Bae et al.   BRITISH JOURNAL OF HAEMATOLOGY

Chronic myeloid leukemia lysate-loaded dendritic cells induce T-cell responses towards leukemia progenitor cells

(2011) Theresia M Westers et al.   Immunotherapy

Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma

(2011) J Bae et al.   LEUKEMIA

In Silico Analysis of Six Known Leishmania major Antigens and In Vitro Evaluation of Specific Epitopes Eliciting HLA-A2 Restricted CD8 T Cell Response

(2011) Negar Seyed et al.   PLoS Neglected Tropical Diseases

Oxygen-Dependent Gene Expression in Development and Cancer: Lessons Learned from the Wilms’ Tumor Gene, WT1

(2011) Holger Scholz et al.   Frontiers in Molecular Neuroscience

Comparative analysis of predicted HLA binding of immunoglobulin idiotype sequences indicates T cell-mediated immunosurveillance in follicular lymphoma

(2010) A.-M. Strothmeyer et al.   BLOOD

Epitope Discovery and Their Use in Peptide Based Vaccines

(2010) Nadine L. Dudek et al.   CURRENT PHARMACEUTICAL DESIGN

A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma

(2010) M. Hussein et al.   HAEMATOLOGICA

Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models

(2010) Silvestre Vicent et al.   JOURNAL OF CLINICAL INVESTIGATION

Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells

(2010) S Bafna et al.   ONCOGENE

Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity

(2010) Daniel E. Speiser et al.   SEMINARS IN IMMUNOLOGY

An operational definition of epigenetics

(2009) S. L. Berger et al.   GENES & DEVELOPMENT

Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma

(2009) F. van Rhee et al.   MOLECULAR CANCER THERAPEUTICS

Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers

(2008) C. Lundegaard et al.   BIOINFORMATICS

CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma

(2008) E. D. Hsi et al.   CLINICAL CANCER RESEARCH

Paradigm Shifts in Cancer Vaccine Therapy

(2008) Jeffrey Schlom et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

Chimeric NKG2D receptor–expressing T cells as an immunotherapy for multiple myeloma

(2008) Amorette Barber et al.   EXPERIMENTAL HEMATOLOGY

Strategies used for MUC1 immunotherapy: preclinical studies

(2008) Choon-Kit Tang et al.   Expert Review of Vaccines

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

(2007) Y.-T. Tai et al.   BLOOD